Directly from the USA: Multitarget Stool DNA Test Has Higher Sensitivity for CRC Than FIT
A next-generation multitarget stool DNA test has higher sensitivity for colorectal cancer and advanced precancerous lesions than fecal immunochemical testing (FIT), according to a study published in the March 14 issue of the New England Journal of Medicine.
Thomas F. Imperiale, M.D., from the Indiana University School of Medicine in Indianapolis, and colleagues conducted a prospective study to examine a next-generation multitarget stool DNA test in asymptomatic adults aged 40 years or older who were undergoing screening colonoscopy. The sensitivity of the test for colorectal cancer and the specificity for advanced neoplasia were examined as the primary outcomes.
Source: Advances and More licensed by HealthDay
